Comparison of cilostazol and clopidogrel after successful coronary stenting.

Author(s): Lee SW, Park SW, Hong MK, Lee CW, Kim YH, Park JH, Kang SJ, Han KH, Kim JJ, Park SJ

Affiliation(s): Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Publication date & source: 2005-04-01, Am J Cardiol., 95(7):859-62.

Publication type: Clinical Trial; Randomized Controlled Trial

This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.